G1 Therapeutics

G1 Therapeutics

G1 Therapeutics - Innovations in Oncology.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
*

$405m

Valuation: $405m

4.9x EV/Revenue

-11.8x EV/EBITDA

Acquisition
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2017201820192020202120222023
Revenues0000000000000000000000000000
% growth----(30 %)63 %61 %
EBITDA0000000000000000000000000000
% EBITDA margin(119 %)(166 %)-(212 %)(454 %)(263 %)(42 %)
Profit0000000000000000000000000000
% profit margin(117 %)(166 %)-(219 %)(471 %)(288 %)(58 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue105 %138 %-162 %242 %162 %53 %

Source: Company filings or news article

Notes (0)
More about G1 Therapeutics
Made with AI
Edit

G1 Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company with a clear focus on developing and commercializing small-molecule therapeutics for oncology patients. The company was founded in 2008 by Dr. Norman Sharpless, former Director of the National Cancer Institute, and Dr. Kwok-Kin Wong, spinning out of research from the University of North Carolina at Chapel Hill. Their mission centered on discovering methods to protect cancer patients from the harsh side effects of chemotherapy. After its inception as G-Zero Therapeutics, the company rebranded to G1 Therapeutics in 2012. A significant milestone was achieved on May 17, 2017, when the company went public, trading on the NASDAQ under the ticker GTHX. In a pivotal development, Danish pharmaceutical company Pharmacosmos A/S announced its acquisition of G1 Therapeutics in August 2024 for approximately $405 million, a transaction that was successfully completed in September 2024, making G1 a wholly owned subsidiary.

The company's business model is centered on the research, development, and commercialization of its primary asset, COSELA® (trilaciclib). Revenue is generated through direct product sales of COSELA and was previously supplemented by licensing and collaboration agreements. For instance, G1 had a commercialization agreement with Boehringer Ingelheim for COSELA in the U.S. and Puerto Rico and licensed development and commercialization rights to Simcere Pharmaceutical in Greater China. The primary client base consists of oncologists and healthcare providers treating patients with specific types of cancer.

G1's flagship product, COSELA (trilaciclib), is a first-in-class CDK4/6 inhibitor administered intravenously. Its key function is to decrease the incidence of chemotherapy-induced myelosuppression, a condition where bone marrow activity is suppressed, leading to lower levels of red and white blood cells and platelets. This proactive, multilineage myeloprotection helps preserve hematopoietic stem cells and immune system function during chemotherapy. The FDA approved COSELA on February 12, 2021, for adult patients with extensive-stage small cell lung cancer (ES-SCLC) receiving a platinum/etoposide-containing or topotecan-containing regimen. COSELA is administered as a 30-minute IV infusion prior to chemotherapy sessions. While the company has explored trilaciclib for other indications, such as triple-negative breast cancer and colorectal cancer, it has recently refocused its efforts primarily on the ES-SCLC market following disappointing trial results in other areas.

Keywords: oncology, myeloprotection, chemotherapy side effects, small cell lung cancer, CDK4/6 inhibitor, trilaciclib, biopharmaceutical, COSELA, cancer therapy, supportive care

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo